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Abstract 
Objectives Patellar tendinopathy (PT) is a debilitating and prevalent condition that tends to 
affect those who are physically active or engaged in jumping sports. Although tendinopathies 
are known to have a genetic basis, the role of DNA methylation as an epigenetic factor and 
risk determinant for human PT has never been described. 
We sought to determine whether differences existed between the methylation profiles of both 
the TIMP2 and ADAMTS4 gene promoter sequences in a cohort of males having undergone 
surgery for patellar tendinopathy compared to controls.  
Design Case-control epigenetic study using DNA from 10 males with PT and 10 males with 
healthy tendons. 
Methods We used PCR and targeted pyrosequencing to interrogate the methylation profiles 
of CpG sites upstream of both the TIMP2 (4 sites) and ADAMTS4 (6 sites) genes. We 
compared methylation differences between the two groups using t-tests. 
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Results We report no significant (p>0.05) methylation differences within the TIMP2 gene 
promoter between the PT group and controls across the 4 CpG sites investigated. In 
contrast, we detected a significant (p=0.016) difference in the methylation status of 1 CpG 
site, approximately 3 Kb upstream of the ADAMTS4 gene between the PT group and 
controls.  
Conclusions To our knowledge, this is the first study to investigate how DNA methylation 
impacts on the risk of human tendinopathy. Our data indicate that the methylation status of 
the ADAMTS4 gene is altered in patellar tendinopathy and we speculate on how this change 
might modify the patellar tendon extra-cellular matrix environment. 
 
KEY WORDS: Tendon, genetics, epigenetics, sports injury, tendinopathy  
 
  
 
 
Introduction 
 
Patellar tendinopathy (PT), also known as jumper’s knee, is an activity-dependant chronic 
condition characterised by anterior pain to the knee1. Injuries to the patellar tendon are 
common2,3. They account for nearly 30% of knee injuries in US high school athletes4 and are 
prevalent amongst volleyball (45%) and basketball (32%) players alike1. PT is also found in 
military cohorts and the injury can lead to prolonged periods of disability5. Both tendon 
neovascularisation and thickening are associated with PT injuries6,7. Furthermore, some 
authors report the injury to associate with an increase in collagen type III fibres along with 
elevated levels of glycosaminoglycans8. A number of risk factors for PT have been 
tentatively reported in the literature such as increased weight and BMI9 and there is a 
growing body of evidence to suggest that genetics can play a role in the predisposition to 
human tendinopathy9,10. However, to date, and to our knowledge, no single study has 
3 
 
investigated the role of human DNA methylation (as an epigenetic factor) in sports injury 
phenotypes like PT.   
 
DNA methylation occurs when a methyl group binds to a cytosine nucleotide base converting 
it to 5-methylcytosine11. This takes place predominantly in CpG rich regions (CpG islands) 
which are typically located in the promoter regions of genes. DNA methylation tends to down 
regulate gene expression by interfering with the accessibility of genes to transcription 
factors12. Hence, methylation can profoundly affect transcription levels and an epigenetic 
mode of inheritance might significantly modify the effect of genotype upon phenotype. 
Furthermore, methylation results from either directionally programmed changes, part of the 
ageing process, or from stochastic and spontaneous alterations attributed to environmental 
factors 13,14. It is difficult to predict, as of yet, the reason why and at which rate some non-
age-associated CpG sites undergo changes in methylation.  
 
The TIMP2 (tissue inhibitor of metalloproteinase 2) gene encodes a protein that has an 
important role in extra-cellular matrix (ECM) homeostasis as it degrades a number of 
metalloproteinases (MMPs)15. Recently, a single nucleotide polymorphism (SNP) within the 
TIMP2 promoter (rs4789932) was found to associate with Achilles tendon pathology (ATP)15 
where TIMP2 expression levels are altered. For example, Jones and colleagues (2006) 
reported a decrease in TIMP2 expression in tendinopathic tissue compared to healthy 
tendons16 while Karousou et al. (2010) reported the opposite effect17. Interestingly, TIMP2 
expression is under tight epigenetic control and hypermethylation has been shown to switch 
off transcription18. However, the effect of TIMP2 methylation on the risk of PT has not been 
investigated. 
 
The ADAMTS4 (A disintegrin and metalloproteinase with thrombospondin motifs 4) gene 
encodes a protein that degrades aggrecan and a number of other components of the ECM19. 
ADAMTS4 expression has been found to increase in knee osteoarthritis and this might 
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exacerbate the condition by contributing to the elevated degradation of proteogylcans19. 
ADAMTS4 mRNA expression levels have been shown to differ in ruptured Achilles tendons 
compared with normal and tendinopathic tendons20. Furthermore, in an equine tendon model 
ADAMTS4 expression level decreased in response to surgical transection. The decrease 
paralleled an increase in aggrecan, versican and lumican21. Hence, the expression of 
ADAMTS4 likely plays an important role in the tendinopathic process but, as yet, our 
understanding of how ADAMTS4 expression is controlled in tendinopathy is unclear. 
Furthermore, like TIMP2, ADAMTS4 is under epigenetic control and loss of methylation has 
been shown to be responsible for the upregulation of ADAMTS4 protein in osteoarthritic 
cartilage22. 
 
It is known that an individual’s methylation profile may change in response to physical 
activity23. However, somewhat surprisingly, the role that DNA methylation plays, as an 
epigenetic factor, has never been investigated in relation to human tendinopathy. With this in 
mind, the aims of the present study were to establish, for the first time, whether epigenetics, 
in particular DNA methylation, was changed in tissue isolated from patellar tendinopathy 
compared to healthy tissue. Our study specifically focused on the DNA methylation statuses 
of the TIMP2 and ADAMTS4 genes in a targeted approach as both, as discussed above, 
undergo changes in expression during tendinopathy but the mechanisms underlying these 
changes are unknown.  
 
Material and methods 
 
Patellar tendon tissue was obtained from 10 male participants with healthy patellar tendons 
(CON) undergoing ACL reconstruction surgeries using a patellar tendon graft. We also 
obtained 10 patellar tendinopathy (PT) samples from males selected for surgical 
debridement for recalcitrant overuse patellar tendinopathy. All tissue was immediately stored 
at -80oC until processing. The DNA samples used in this study were collected from 
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participants recruited from 2003-2005 that were originally described elsewhere in studies 
focusing only on proteogylcan and RNA levels24. Participant information was obtained from 
surgery theatre lists and was limited to age, sex and ethnicity. Unfortunately, additional 
demographic information such as height, weight, BMI and other relevant medical history 
were not made available to us. Hence our cohort should be considered as a convenience 
sample. All participants were otherwise healthy Caucasians aged from 19 to 41 years and 
gave written informed consent. Approval was obtained from the University of Northampton’s 
School of Health Research Ethics Committee and La Trobe University Human Ethics 
Committee (Application number 12-086). 
 
DNA was obtained from all patellar samples using the PureLink® Genomic DNA Kit 
(Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s recommendations. The 
DNA quantity was determined using a NanoDrop 2000 (Thermo Fisher Scientific, 
Wilmington, DE). The DNA samples (50 ng), in addition to a universal non-methylated 
control DNA sample from the EpiTect® PCR Control DNA Set (Qiagen, Hilden, Germany), 
were bisulfite treated using the EpiTect® fast DNA bisulphite Kit (Qiagen, Hilden, Germany) 
according to the manufacturer’s recommendation. The Pyrosequencing assays for the 
TIMP2 (Hs_TIMP2_01_PM) and ADAMTS4 (Hs_NDUFS_01_PM) genes used in this study 
were selected from the pre-designed PyroMark® CpG Assays (Qiagen, Hilden, Germany). 
The single assay designed for the CpG island within the TIMP2 promoter region measured 
methylation at 4 CpG sites. (-488 bp, -478 bp, -467 bp, and -455 bp from the first exon). The 
assay chosen for the CpG sites within the promoter region of the ADAMTS4 gene was 
selected to cover a wider area of the promoter region and spanned 6 CpG sites that were -
2964 bp, -2973 bp, -2995 bp, -2998 bp, -3000 bp and -3002 bp from the first exon. We took 
a pragmatic approach to the choice of CpG sites that we investigated. In some cases it was 
not possible to study certain regions of the promoters as sequencing assays did not meet 
quality control standards. However, as ADAMTS4 is regulated by a large promoter 
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sequence25, we were especially interested to determine how methylation of CpG sites that 
are distant to the transition start site impacted on injury risk. 
 
All bisulfite converted DNA samples in addition to hypermethylated and hypomethylated 
controls were PCR amplified using the pre-designed primer sets of the PyroMark® CpG 
Assays (Qiagen, Hilden, Germany). A Techne TC-512 thermocycler (Bibby Scientific Ltd, 
Staffordshire, UK) was used to amplify the target sequences according to the manufacturer 
protocol. To confirm successful PCR amplification the products were run on a 1x agarose gel 
alongside a GeneRulerTM 100 bp ladder (MBI Fermentas, UK). The biotinylated PCR 
products were then immobilised to Streptavidin-coated Sepharose high-performance beads 
(GE Healthcare, Buckinghamshire, UK) according to the PyroMark® Q24 manufacturer’s 
recommendations (Qiagen, Hilden, Germany). The immobilised PCR products were 
captured using the PyroMark® Q24 vacuum (Qiagen, Hilden, Germany) and released into a 
24 well PyroMark® Q24 plate containing 1x sequencing primer diluted in 25 μl PyroMark® 
Annealing Buffer. Before placing the Q24 plate into the pyrosequencer, the sequencing 
primer was allowed to anneal on a preheated hot-plate at 80 °C for 2 min followed by room 
temperature incubation for 10 min. Following pyrosequencing, pyrograms were visualised 
and percentage methylation of the CpG sites was determined using the PyroMark® Q24 
v2.0.6 software. Data analysis was performed using SPSS Version 20 program (IBM Corp. 
Armonk, NY). A t-test was used to compare the mean percentage methylation of each CpG 
site between the CON and the PT samples for both the TIMP2 and ADAMTS4 CpG sites. 
Significant differences in methylation were called when p<0.05. Correction for multiple 
testing was not conducted for reasons previously described by Posthumus et al (2011) 26 
 
Results 
PCR products for the TIMP2 and ADAMTS4 promoter sequences investigated were 
detected as single bands with the expected amplicon lengths (154 bp and 244 bp 
respectively) as shown in figure 1. Typical pyrograms obtained showing percent methylation 
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at the 4 CpG sites for TIMP2 (panels A and B) and the 6 CpG sites for ADAMTS4 (panels C 
and D) can be seen in figure 2. In our cohort the CON and PT groups were similarly matched 
for age (p=0.449) and gender. For TIMP2 we found no significant difference (p=0.885) in the 
mean methylation percentages across all 4 sites between the CON and the PT groups. 
Furthermore, there was no significant difference in methylation for any of the 4 CpG sites 
when analysed independently between the CON and the PT groups as shown in figure 3. 
However, for the ADAMTS4 gene, CpG site 3 was significantly (P=0.016) more methylated 
in the PT group compared to the CON group (figure 3). Further data analysis showed no 
significant difference between CON and PT in the remaining 5 sites when analysed 
independently (figure 3), or for the mean percentages of methylation across the 6 sites 
(p=0.294).  
 
Discussion 
 
To our knowledge, this is the first study to investigate DNA methylation differences in 
clinically resected human tendinopathy samples compared to healthy tendon tissue. Unlike 
the recent study of Trella and co-workers27 who used a genome wide design in a mouse 
tendinopathy study, we employed a hypothesis-driven, targeted approach to study 
methylation profiles of two genes (TIMP2 and ADAMTS4) that have been associated with 
the tendinopathic process in human15,20. 
 
TIMP2 is known to be under epigenetic control with a CpG island in the promoter region of 
the gene extending from the transcription initiation site upstream for approximately 900 bp18. 
The methylation of the CpG sites located between positions -295 and -145 bp was found to 
reduce the expression of TIMP2 in prostate cancer samples18. Likewise, the overlapping 
region ranging from -350 to -240 bp was also found to be over-methylated in cervical 
cancer28. However, our work showed that there were no methylation changes within the CpG 
Island ranging from position -488 to -455 between the CON and PT tissue samples. 
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Moreover, all analysed samples showed very low methylation levels which might infer that 
this region of the TIMP2 promoter is not involved in regulating TIMP2 expression or 
deregulation during the process of patellar tendinopathy. Furthermore, the lack of change in 
TIMP2 methylation status between PT tissue and controls shown here is consistent with the 
absence of TIMP2 expression level changes between PT and control tissue previously 
shown by Parkinson et al (2010)24. The fact that we found no difference in TIMP2 
methylation status between PT tissue and controls it interesting. This might suggest that 
previously observed differences in TIMP2 expression in Achilles tendinopathy17 are not an 
active part of the tendinopathic process but possibly no more than an artefact of the injury. 
Of course, we only interrogated a small number of CpG sites for TIMP2 in this study and 
investigating a larger area might well have revealed significant differences between the PT 
and CON samples.  
 
Of the 6 CpG sites investigated 3 kb upstream of the ADAMTS4 gene we found one site, 
located at position -2995, that was significantly (p=0.016) more methylated in the PT group 
compared to the CON group. Although only one of the 6 CpG sites was more methylated in 
the tendinopathic tissue compared to controls, the impact of this when considering the risk of 
patellar tendinopathy might be far reaching. To be specific, the ADAMTS4 gene is known to 
be under epigenetic control22 and regulated by a large promoter (-4109 to +406) that 
consists of two NFAT and several Runx binding elements25. One of the NFAT binding 
regions resides only 103 bp away from the CpG site that we investigated and it is plausible 
that a change in methylation status at that site, as measured by us, could affect the binding 
of NFAT transcription factors and alter the expression of ADAMTS4. Interestingly, an 
increase in the accumulation of proteoglycans including aggrecan was found previously in 
PT tissue taken from the participants in this study24 and others29. However, somewhat 
surprisingly, ADAMTS4 levels in this patient cohort did not differ compared to controls24. 
Recently, the expression of ADAMTS4 was shown to decrease, in a region specific manner, 
in an ovine model of tendinopathy30. The reduction in ADAMTS4 expression was found to be 
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commensurate with an increase in aggrecan30. Therefore, we speculate that in some 
situations the accumulation of proteoglycans such as aggrecan may be explained, at least in 
part, by reduced levels of ADAMTS4 caused by hypermethylation at CpG sites within the 
ADAMTS4 gene promoter. It is also worth noting that methylation change at single CpG sites 
can have profound effects on phenotypes. For example, Fürst and colleagues31 have 
observed this phenomenon with respect to the expression of estrogen receptor alpha 
(ESR1) and methylation changes at single sites upstream of the SLC23A2 and NCOR2 
genes have been shown to influence the severity of spinal muscular atrophy32.  
 
Although our study was the first, to our knowledge, to report DNA methylation changes 
associated with human tendinopathy there were some limitations. Firstly, although our 
participants were all male with no significant age differences between the PT cases and 
controls we were unable to control for height, weight or level of physical activity in our 
dataset as this information was not available to us. The acquisition of such data in future 
experiments would improve confidence in the interpretation of the results. Secondly, our 
study was limited to a small number of clinical samples that were available from Caucasian 
men. Therefore, the changes we observed may not represent methylation changes that 
might occur in other populations. Hence, this work should be validated in larger, non-
Caucasian cohorts and in female patients. Finally, this study has revealed that an over-
methylation event in the promoter sequence of the ADAMTS4 gene associates with patellar 
tendinopathy. The hypermethylated CG site sits close to an important DNA regulatory 
element and might influence risk of tendinopathy by modifying ADAMTS4 levels leading to 
structural or regulatory changes within the ECM components of the tendon. Such changes 
might predispose an individual to develop the injury.  
 
Conclusions 
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We provide the first evidence that DNA methylation (an epigenetic factor) within the 
promoter sequence of the human ADAMTS4 gene might be important in patellar 
tendinopathy. Our data have clear implications as set out below: 
 
Practical implications 
 As DNA methylation changes are modified by the environment it might be possible, in 
the future, to alter methylation status, through adaptions to an athlete’s training 
programme, to reduce the risk of tendinopathy.  
 
 DNA methylation changes might well explain discrepant gene association findings 
that have been observed in some studies on human tendinopathy. 
 
 DNA methylation, as an epigenetic factor, should be considered as a potential 
modifier of genotype and other biochemical factors when considering risk of 
tendinopathy. 
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FIGURE 1. Agarose gel (1%) electrophoresis images of the TIMP2 and ADAMTS4 gene promoter 
sequences investigated. Panel A (TIMP2): Well 1, 100 bp ladder; well 2, no DNA (negative control); 
well 3 and 4, control samples; wells 5 and 6, DNA from PT; well 7, hypermethylated control; well 8, 
hypomethylated control; well 9, no DNA (negative control) and well 10 bisulphite converted 
hypomethylated control. Panel B (ADAMTS4): Well 1, 100 bp  ladder; wells 2 and 4, control DNA 
samples; wells 5 to 7, DNA from PT; well 8, hypermethylated control; well 9, hypomethyated control; 
well 10, bisulfite converted hypomethylated control and well 11, no DNA (negative control). Gels were 
run as described in the Materials and Methods section. 
 
 
 
 
FIGURE 2. Typical pyrograms showing the methylation status of the TIMP2 and ADAMTS4 gene 
promoter sequences investigated from both control and PT patients. Panel A: Percent methylation at 
each of the four CpG sites within the TIMP2 gene promoter from healthy tendon. Panel B: Percent 
methylation at each of the four CpG sites within the TIMP2 gene promoter from a patient with patellar 
tendinopathy. Panel C: Percent methylation at each of the six CpG sites within the ADAMTS4 gene 
promoter from healthy tendon. Panel D: Percent methylation at each of the six CpG sites within the 
ADAMTS4 gene promoter from a patient with patellar tendinopathy. In each figure the grey boxes 
indicate the percentage of each CpG site that is methylated in the sample that is run.  
  
 
FIGURE 3. Bar graphs showing the mean (± SD) percent methylation status at each of the CpG sites 
investigated within the TIMP2 (Panel A) and ADAMTS4 (Panel B) gene promoter sequences. For both 
genes the CpG sites for healthy tendons are shown as white bars and those for tendinopathic tendons 
are shown as black bars. 
*p=0.016.  
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FIGURE 1 Panel A 
 
 
 
 
 
 
 
FIGURE 1 Panel B 
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FIGURE 2 Panel A 
 
 
 
FIGURE 2 Panel B 
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FIGURE 2 Panel C 
 
 
 
FIGURE 2 Panel D 
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